Topics

Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test for Monitoring Disease Burden in CML Patients

10:53 EDT 2 Oct 2019 | Speciality Pharma Journal

SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ — Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden in patients with Chronic Myeloid Leukemia (CML). Xpert BCR-ABL Ultra, an in vitro diagnostic test, is the first FDA-cleared test of its kind capable of …

Original Article: Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test for Monitoring Disease Burden in CML Patients

NEXT ARTICLE

More From BioPortfolio on "Cepheid Receives FDA Clearance for Xpert BCR-ABL Ultra Test for Monitoring Disease Burden in CML Patients"

Quick Search